Indian biotech startup StrainX Bioworks has raised $13 million, or nearly ₹124 crore, as the company officially entered the public space after spending two years in stealth mode. The startup works in synthetic biology and precision fermentation, two fast-growing areas in the biotech industry. The company plans to use the fresh capital to grow its business, increase production capacity, and move toward large-scale commercial operations.
The funding round was led by Prime Venture Partners and Leo Capital. Other investors in the round include Good Startup, Sparrow Capital, Sun Icon Ventures, Dholakia Ventures, and WindT Angels, which is linked to IIT Delhi alumni.
Founded by IIT Delhi Alumni
StrainX was founded by Akshay Mittal and Alok Malaviya, both connected to IIT Delhi. During the last two years, the company quietly built its scientific and technical systems while staying away from public attention. The founders focused on research, product development, and process design before making the company public.
The startup now has more than 100 scientists, engineers, and operators. The team has developed a full biotechnology platform that covers strain engineering, fermentation, process scale-up, and product development. This wide setup allows the company to control many parts of the manufacturing process under one system.
Focus on Synthetic Biology and Precision Fermentation
StrainX works in synthetic biology and precision fermentation, which are becoming important technologies across many industries. These systems use biological methods to create products in a cleaner and more sustainable way compared to traditional manufacturing methods.
Precision fermentation allows companies to produce ingredients and proteins with the help of microbes and biological processes. Many firms across the world now use this technology in food, nutrition, materials, and consumer health products.
The demand for sustainable manufacturing systems has increased in recent years. Companies and consumers now want products that create less environmental damage and reduce pressure on natural resources. StrainX believes biotechnology can solve many of these problems.
Plans for Large-Scale Production
The startup has already completed large-scale fermentation trials and now plans to move toward much bigger operations. According to the company, it is preparing pathways for fermentation systems that can handle up to 100,000 litres in the near future.
The company also plans to expand its bio-manufacturing fermentation facility in Bhopal. This expansion will help StrainX start commercial-scale production in the coming months.
The fresh funding will support infrastructure growth, scientific research, team expansion, and global business partnerships. The company wants to increase its presence in international markets as well.
Founders Speak About the Future of Biology
Akshay Mittal, founder and chief executive officer of StrainX, said biology may become a new manufacturing layer for the world in the coming years. He believes products across food, materials, and consumer sectors may increasingly depend on biological systems instead of older industrial methods.
Mittal also said India has the scientific talent and engineering strength needed to become a global leader in this field. According to him, StrainX started at the right time to support this industry shift.
Co-founder and chief technical officer Alok Malaviya said India is no longer just a biotech manufacturing base. He believes the country is slowly becoming a global hub for innovation in synthetic biology and precision fermentation.
Investors Show Confidence in Deep-Tech Biotech
Investors in the funding round have shown strong confidence in the company’s scientific approach and business model. Brij Bhushan, managing partner at Prime Venture Partners, said StrainX stood out because it combines strong science with smart business execution.
Rajul Garg, founder and managing partner at Leo Capital, described StrainX as a deep-tech biotech company that carries both ambition and discipline. Investors believe the company has the ability to scale in global markets due to its strong technical base and growing production systems.
Good Startup, a Singapore-based investor that mainly backs biotech firms, also joined the round. This marked its first investment in India. Gautam Godhwani, managing partner at Good Startup, said India’s talent pool, infrastructure, and cost advantages make the country suitable for global precision fermentation innovation.
India’s Biotech Sector Gains Strength
India’s biotech industry has grown rapidly in recent years. The country now has thousands of biotech startups that work across healthcare, agriculture, food technology, industrial biotechnology, and AI-driven drug discovery.
Reports suggest India’s bioeconomy may become a $300 billion market opportunity by 2030. This growth has attracted strong investor interest toward deep-tech and biotech startups.
Many startups now focus on sustainable production systems, alternative proteins, and biological manufacturing because global demand continues to rise. Companies also want supply chains that depend less on traditional industrial systems.
StrainX Looks Toward Global Expansion
As StrainX steps into the public market, the company plans to focus heavily on research and commercialization. It wants to strengthen its scientific and engineering teams while also building global partnerships for large-scale production and supply.
The company believes biotechnology may change the future of manufacturing across many industries. With fresh funding, a large scientific team, and expanding production systems, StrainX now plans to position itself as one of India’s important biotech startups in the precision fermentation space.
The funding also highlights growing investor interest in Indian deep-tech startups that combine science, engineering, and scalable business models. If StrainX succeeds in expanding commercial production, the company may become an important player in the global biotechnology market over the next few years.
Also Read – What Is a Unicorn Startup?